Yesterday, one of Becky's doctors shared a brief article with her
concerning EMF (electromagnetic fields). I have found the source for the
article via the PubMed MedLine search engine. The specific search page
URL follows.
http://www.ncbi.nlm.nih.gov/Entrez/medline.html
I used the PubMedID (7744555) as the search criteria with the expectation
that I copy the specific article into this message to share it. I have
done so below, however, there are a whole mess of related articles, hence
this information to allow any who choose to view them.
The text from the one message follows:
UI - 95263219
AU - Sandyk R
TI - A drug naive parkinsonian patient successfully treated with weak
electromagnetic fields.
LA - Eng
MH - Affect
MH - Case Report
MH - Cognition
MH - Dopamine
MH - *Electromagnetic Fields
MH - Human
MH - Male
MH - Memory
MH - Middle Age
MH - Parkinson Disease/*therapy
MH - Serotonin
MH - Sleep
RN - 50-67-9 (Serotonin)
RN - 51-61-6 (Dopamine)
PT - JOURNAL ARTICLE
DA - 19950614
DP - 1994 Nov
IS - 0020-7454
TA - Int J Neurosci
PG - 99-110
SB - M
CY - ENGLAND
IP - 1-2
VI - 79
JC - GS4
AA - Author
EM - 199508
AB - Brief cerebral application of picotesla (pT) electromagnetic fields
(EMF) has been demonstrated an efficacious, revolutionary treatment
modality for the therapy of Parkinson's disease (PD) with clinical
benefits being evident in all motor aspects of the disease as well as
in nonmotor symptoms such as mood, sleep, pain, sexual dysfunction,
autonomic regulation and cognitive functions. Since treatment with pT
EMF has involved PD patients who were treated with dopaminergic agents
at the time they received EMF there may have been a synergistic
interaction between dopaminergic drugs and EMF. The present
communication concerns a 49-year-old male Parkinsonian patient with
stage 3 disability on the Hoehn and Yahr scale (1967) who, in response
to brief extracranial applications of pT EMF, demonstrated a marked
improvement in motor, depressive symptomatology and cognitive functions
and was classified as stage 1 several weeks later. This case is
remarkable in that the patient did not receive treatment with
dopaminergic drugs prior to or during the course of EMF therapy. It
suggests that (a) pT range EMF may be efficacious as a monotherapy for
PD and should be considered also as a treatment modality for de novo
diagnosed patients, and (b) application of these EMF improves
Parkinsonism by a mechanism which involves, among others, augmentation
of dopaminergic and serotonergic neurotransmission.
AD - NeuroCommunication Research Laboratories, Danbury, CT 06811, USA.
PMID- 0007744555
SO - Int J Neurosci 1994 Nov;79(1-2):99-110
Maybe this will help some who wrestle with this designer disease called
Parkinsons.
Jeff Jones, PT CG for Becky
[log in to unmask]
